Search Results
187 results
Your search is now limited to «Takeda» expert search.
pharmaphorum 01/22/2019 07:32
The Shire takeover turned Takeda into one of the world’s biggest 10 pharma companies, but doubled its borrowing and prompted S&P Global Ratings and Moody’s Investors Service to cut its credit rating.
More from pharmaphorum:
NASDAQ 01/21/2019 21:02
No decisions have been made regarding specific assets for potential disposal at this stage," a spokeswoman for Takeda reportedly said.
More from NASDAQ:
PharmaTimes 01/21/2019 12:04
Jon has been Managing Director of Takeda UK and Ireland since May 2018, having been with the company for a decade and bringing a wealth of experience in senior roles within the UK pharmaceutical industry.
More from PharmaTimes:
Egypt- Takeda Pharmaceutical organises the first Hodgkin lymphoma regional summit.
More from Middle East North Africa Financial Network (MENAFN):
PR Newswire 01/14/2019 15:48
While Xeljanz's oral formulation bodes well for the drug to successfully penetrate the first-line patient segment, other factors including market access issues and product labeling could be preventing earlier uptake.
More from PR Newswire:
Law360 01/14/2019 15:28
Baker Botts LLP can continue representing Zydus Pharmaceuticals as it pursues antitrust claims against Takeda over a heartburn medication, despite the law firm’s prior representation of Takeda’s ally in patent litigation over the same drug, a New Jersey federal judge said in a ruling made public Friday.
More from Law360: 01/11/2019 08:50
The Lonza team in Tampa, FL (USA) collaborated with Takeda to provide support from early drug product.
More from
BioPharma-Reporter 01/10/2019 05:55
In a statement, Stefan Wildt, head of pharmaceutical sciences at Takeda, said, “There’s an incredible opportunity to combine promising external innovation with the power of a fit-for-purpose translational cell therapy engine to accelerate the development of truly novel cell therapies.
More from BioPharma-Reporter:
ENDPOINTS 01/09/2019 08:10
Takeda bought the Swiss drugmaker for its smoker’s lung drug and its OTC portfolio in an attempt to expand its footprint in emerging markets, but as market conditions worsened, the deal invited a storm of criticism.
More from ENDPOINTS:
BioPharma Dive 01/09/2019 01:59
The pharma aims to reduce its net debt to two times earnings before interest, taxes, depreciation and amortization (EBITDA) over the next three to five years — a timeline that could change depending on the degree to which Takeda divests assets ...
More from BioPharma Dive:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications